Last quarter (Q ), Algernon Pharmaceuticals's total revenue was C$―, a decrease of ― from the same quarter last year. In Q, Algernon Pharmaceuticals's net income was C$-2.53M. See Algernon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Aug 23	Aug 22	Aug 21	Aug 20	Aug 19
Total Revenue	-	-	-	-	-	C$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	C$ 5.24M	C$ 5.24M	C$ 6.06M	C$ 8.05M	C$ 8.66M	C$ 1.91M
Operating Income	C$ -5.24M	C$ -5.24M	C$ -6.06M	C$ -8.05M	C$ -8.66M	C$ -1.91M
Net Non Operating Interest Income Expense	C$ 2.10K	C$ 2.10K	C$ 2.08K	C$ -11.93K	C$ -35.08K	C$ 6.72K
Other Income Expense	-	-	-	C$ 305.12K	C$ 87.77K	C$ 11.62K
Pretax Income	C$ -6.78M	C$ -6.78M	C$ -6.05M	C$ -7.73M	C$ -8.54M	C$ -1.90M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	C$ -6.78M	C$ -6.78M	C$ -6.05M	C$ -7.73M	C$ -8.54M	C$ -1.90M
Basic EPS	C$ 0.94	C$ 0.45	C$ 3.48	C$ -1.24	C$ -2.50	-
Diluted EPS	C$ 0.94	C$ 0.45	C$ 3.48	C$ -1.24	C$ -2.50	-
Basic Average Shares	C$ 53.45M	C$ 15.15M	C$ 1.74M	C$ 6.23M	C$ 3.52M	-
Diluted Average Shares	C$ 53.45M	C$ 15.15M	C$ 1.74M	C$ 6.23M	C$ 3.52M	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	C$ 5.24M	C$ 5.24M	C$ 6.06M	C$ -8.05M	C$ -8.66M	C$ 1.91M
Net Income From Continuing And Discontinued Operation	C$ -6.78M	C$ -6.78M	C$ -6.05M	C$ -7.73M	C$ -8.54M	C$ -1.90M
Normalized Income	C$ -3.44M	C$ -3.44M	C$ -4.45M	C$ -5.68M	C$ -6.36M	C$ -1.91M
Interest Expense	-	-	-	-	-	-
EBIT	C$ -6.78M	C$ -6.78M	C$ -6.05M	C$ -7.73M	C$ -8.54M	C$ -1.91M
EBITDA	C$ -6.73M	C$ -6.73M	C$ -6.02M	C$ -7.73M	C$ -8.54M	C$ -1.89M

Currency in CAD

Algernon Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing